The purpose of this review is to highlight the current progress, controversies, and challenges in the development of protein, gene, and cell-based approaches for clinical therapeutic angiogenesis.
We compared outcomes with conventional (CCPB) and miniaturized cardiopulmonary bypass (MCPB) after coronary artery bypass operations (CABG) with respect to inflammation and coagulation.